maplirpacept + azacitidine

Combination of **maplirpacept** (also known as TTI-622, a recombinant fusion protein composed of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4) and **azacitidine** (a hypomethylating agent). Maplirpacept acts as a CD47 decoy receptor, inhibiting the "don't eat me" signal by blocking CD47–SIRPα interaction and promoting macrophage-mediated phagocytosis of tumor cells, including those in AML and MDS. **Azacitidine** acts as a DNA methyltransferase inhibitor, inducing cellular differentiation and apoptosis in abnormal hematopoietic cells. The combination is under clinical investigation, especially for TP53-mutated acute myeloid leukemia (AML), with the goal of enhancing anti-tumor phagocytosis while minimizing anemia, a common adverse event in anti-CD47 therapy[1][3].

Other names

TTI622 + azacitidine